UK Valproate Restrictions in Men Justified? New Data
As previously reported by Medscape Medical News , the decision to restrict the drug in women and in men younger than 55 years was made in January 2024, after the UK Medicines and Healthcare products Regulatory Agency issued new guidance on the drug's use.
'Paternal exposure to antiseizure medication in association with conception is unlikely to pose any major risk for the offspring,' the investigators led by Jakob Christensen, DrMedSci, consultant neurologist at Aarhus University Hospital and professor at Aarhus University, Aarhus, Denmark, noted.
The study was published online on May 22 in JAMA Network Open .
Unnecessary Precaution?
In the US and Europe, there is strong guidance about avoiding valproate in pregnant women and women of childbearing age due to an elevated risk for birth defects and other developmental problems.
In January 2024, the European Medicines Agency's (EMA's) safety committee (Pharmacovigilance Risk Assessment Committee [PRAC]) expanded precautionary measures on valproate use to men considering fatherhood. The advisory was fueled largely by an observational study by the contract research organization IQVIA.
The study showed that about 5 out of 100 children had an NDD when born to fathers taking valproate during the 3 months before conception compared with about 3 out of 100 when born to fathers treated with lamotrigine or levetiracetam.
Last summer, Christensen and colleagues were unable to replicate the IQVIA results in a study using a subset of the same IQVIA data. However, at the time, only limited information about the IQVIA study was publicly available.
Once additional information from the IQVIA study became available, the researchers tried again to replicate the findings, aligning their methods more closely with the IQVIA study.
Despite using the same methodology and incorporating additional data, they were still unable to replicate the IQVIA findings. Their conclusion remained unchanged — there was no statistically significant increased risk for NDDs.
Specifically, among 961 children exposed to paternal valproate monotherapy and 1401 exposed to lamotrigine or levetiracetam, there was no significant increase in risk for NDDs (adjusted hazard ratio [aHR], 1.02; 95% CI, 0.67-1.54).
'This finding remained robust across analyses of specific NDDs, analyses of valproate dose, analyses accounting for time trends, analyses allowing for polytherapy, analyses expanding the definition of NDDs, analyses restricted to fathers with epilepsy, and analyses with a restricted exposure window,' Christensen and colleagues reported.
Restricting analyses to fathers with epilepsy of unknown cause yielded a higher risk (aHR, 2.48; 95% CI, 1.13-5.44), but this association was no longer significant in analyses matched on birth year (aHR, 2.33; 95% CI, 1.00-5.44).
Additional sensitivity analyses (restricting exposure window, excluding children with epilepsy or maternal epilepsy, and accounting for polytherapy) consistently showed no elevated risk for NDDs associated with paternal valproate exposure.
'We've examined this issue from many angles and still find no evidence supporting the concern behind EMA's recommendations,' Christensen said in a news release.
Will the EMA Reconsider?
Reached for comment, Aatif Husain, MD, epileptologist, neurologist, and sleep medicine specialist at DukeHealth, Durham, North Carolina, said, 'There seems to be a fair amount of literature' suggesting no increased risk for NDDs in children whose fathers use valproate.
'A recent systematic review that included 10 other studies came to this same conclusion,' said Husain, who wasn't involved in the Danish study.
Taken together, the data 'would probably move EMA to relook at their guidance to see if it needs to be modified,' he said.
Medscape Medical News reached out to the EMA press office for comment and received the following response.
'As with every medicine authorized in the EU, EMA continues monitoring and supervising the safety of these medicines. This includes monitoring information from various sources, such as spontaneous reports, clinical studies, scientific literature, and management of safety signals, which consists of a set of activities to determine whether there are new risks associated with an active substance or a medicine or whether known risks have changed. Should there be any updates, EMA will communicate them via the PRAC Highlights.'
Husain told Medscape Medical News that neither the FDA nor the American Epilepsy Society has issued guidance on valproate use in men 'because the data has not been strong enough.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NHS: Strike-hit appointments to be rebooked in two weeks but will impact others
NHS England has said hospitals are aiming to reschedule appointments cancelled due to strikes within two weeks, but warned of knock-on impacts for other patients. Professor Meghana Pandit, NHS England's co-national medical director (secondary care), said that despite the five-day walkout by thousands of resident doctors in England, which began on Friday, local trusts have managed to maintain services with 'minimal disruption'. She told BBC Breakfast: 'If there's any rescheduling or postponement of surgery or appointments then the hospitals try their upmost best to get that appointment rescheduled within two weeks. 'I know it is distressing and even two weeks is too long for somebody to wait and actually that has an impact on the people who who are then displaced at that two week period.' Prof Pandit said there were three 'derogations' granted on Friday, a process which allows hospitals to request striking doctors return to work if there is a risk to patient safety. Nottingham City Hospital reached an agreement with the British Medical Association (BMA) to exempt one doctor from the strike to work on the neonatal intensive care unit. A derogation was agreed for one doctor in the emergency department and another doctor in the ISGM at the Northern General Hospital. The BMA said it had also agreed a derogation for two anaesthetists to work at University Hospital Lewisham on Saturday to ensure patient safety. It comes as Wes Streeting said 'we are doing everything we can to minimise' patient harm. The Health Secretary condemned the strike as 'reckless' and said the Government would not allow the BMA to 'hold the country to ransom'. Sir Keir Starmer made a last-minute appeal to resident doctors, saying the strikes would 'cause real damage'. He added: 'Most people do not support these strikes. They know they will cause real damage… 'These strikes threaten to turn back the clock on progress we have made in rebuilding the NHS over the last year, choking off the recovery.' The BMA has argued that real-terms pay has fallen by around 20% since 2008, and is pushing for full 'pay restoration'.
Yahoo
2 hours ago
- Yahoo
Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 14, the company delivered positive clinical data from the Phase 3 PaTHway Trial, which affirmed that TransCon PTH (palopegteriparatide) offered benefits to adults with hypoparathyroidism. A close-up of a pharmacist in a gleaming white labcoat holding a vial of biopharmaceuticals. Hypoparathyroidism is an endocrine disorder characterized by a deficiency of parathyroid hormone, which regulates the balance of calcium and phosphate. Serious side effects from the illness can include cognitive decline, renal problems, and neuromuscular irritability. The new three-year data for the Phase 3 PaTHway Trial, presented at the ENDO 2025 conference, showed improvements in biochemical markers, kidney function, and quality of life. Kidney function was maintained through week 156, as the mean glomerular filtration rate (eGFR) increased by 8.76 mL/min/1.73 m². No new safety concerns emerged during the trial phase, as the treatment was well-tolerated. 'These responses, including normalization of skeletal dynamics with significant and clinically meaningful improvements in kidney function, demonstrate the long-term benefits of this treatment option for the vast majority of adults with hypoparathyroidism,' said Aimee Shu, Executive Vice President and Chief Medical Officer at Ascendis Pharma. Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops new therapies to address unmet medical needs using the innovative TransCon technology platform. It focuses on rare endocrine diseases and oncology, with the goal of creating best-in-class treatments. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
'I'm an unpaid carer for my mum in Greenwich - it's like grieving your own life'
Seven years ago Denise Wilkins was a successful accountant who was regularly travelling across Europe for her work. Her career achievements were remarkable considering she had been simultaneously caring for her mum, Maureen Shields, since the age of 14 when she started to lose her sight. But in 2018 everything changed. Maureen woke up one morning and couldn't move. She'd developed osteoporosis, a condition which weakens bones and makes them more susceptible to fractures. Maureen had spinal fractures that prevented her movement and caused her excruciating pain. Denise was forced to give up the career she'd worked so hard to build to look after Maureen full-time. Denise, now 54, said: 'It's almost like grieving the loss of your own life. You're grieving because of the loss of what's happened to somebody else, and seeing somebody in constant pain is hard. "It's also just incredibly mentally and emotionally wearing having to not only deal with your own life's disappointments and problems, but also the emotions that they're going through.' Denise lives with her 89-year-old mum in a flat in Vanbrugh Hill, Greenwich and has said the experience has had a profound impact on her mental health and wellbeing, to the point that she's been prescribed antidepressants to cope. Never in doubt was it that she would be there for her mum, but the lack of support from the government for unpaid carers like her has led to burnout and a feeling of being abandoned. 'There's a lack of support, a lack of understanding, and a lack of recognition,' Denise said. 'I just don't think people really understand just how all time consuming it is, and to be honest, it is very emotionally draining.' After the osteoporosis diagnosis the family moved from Loughton in Essex – their home for over 20 years – to Greenwich in order to be closer to King's College Hospital and because they couldn't adapt their Essex home to Maureen's needs. Maureen had a series of operations which stabilised her condition, but it left her with virtually no mobility. Denise has looked after her mum on a near daily basis since then as she can't afford to get paid carers in to help. She praised the work the NHS did in treating Maureen, but was critical of the provision for care that is provided afterwards. She said: 'There is just this assumption that the family's going to step in. There is nothing wrong with that, but then you realise there is very little support out there to recognise what you've lost in your life. It was life-changing for her, but it was also life-changing for me.' Denise felt that since she started looking after her mother in 2018, she has massively missed out on living her own life. She said: 'I mean not just financially, career-wise, socially, but all hobbies and interests have been completely put on hold. Even things like your own fitness levels and personal relationships. 'You feel like it's not just the person who needs to be cared for whose life has changed. It's almost like you've got an illness too.' Denise said she even has trouble attending to her own medical needs due to the lack of available appointments. If she's not able to find someone to look after her mum at the time when a GP appointment is offered, she can't attend it. Denise said she has been on antidepressants for the past six years, something she directly attributed to the stress of being a full-time carer. She is often told by people to take a break, but that is something that is incredibly difficult for her because she would need to find someone Maureen is comfortable with, who is able to look after her and she is able to afford. Her own retirement is in doubt Since becoming a carer, Denise hasn't been able to pay into her pension. For work, she has been able to pick up some zero-hour flexible contracts for minimum wage. 'While you're going through this journey you talk to other people and you find that it's common across the board,' she said. 'You start to realise that if people weren't stepping in and doing what they were doing, the whole adult social care system would just collapse.' Denise was critical of the government's stance on adult social care. She said: 'I can remember for at least the last 10 years that it's going to be reviewed. There's been loads of these reports, and you just feel like saying to people, 'Come on, we need to address this'. 'We need to, not just as individuals but as a society, look at how we're going to handle this.' When asked what changes she would like to see the government make to adult social care and the role of carers, Denise said: 'I think they could really do a lot more in terms of allowing carers to have time off, especially with work. 'You're allowed to take two or three days' unpaid leave, but that's nothing. It doesn't even begin to cover the number of hospital appointments that you'll need to attend.' She also hoped that a system could be brought in that would allow for carers to be registered and recognised. 'It would allow us to be able to go to employers and people and say, 'I am a registered carer'.' Denise also wanted the government to recognise that often carers are skilled workers who could be put to use helping society if there was more of a push to get them to work from home. 'There's a whole skill base out there of people like me who have got the qualifications and have got the work experience,' she said. 'I think that's another frustrating thing. They go off and supposedly do these reviews, but they never ever seem to talk to us. We're not just sitting here complaining. We actually feel that we've got things we could suggest.' Protest outside Parliament In an attempt to drive the issue of carers into the public eye and onto the government agenda, Denise took part in a protest on Tuesday (July 22) outside Parliament. As she can't get away from her caring duties, Denise wasn't there in person. Her story, alongside those of several other unpaid carers, will be broadcast on LED screens outside government buildings in an attempt to get politicians to listen. The protest, which was set up by Uncommon Creative Studio and is backed by charity Carers Trust, has been launched in conjunction with a petition which calls on the government to give all unpaid carers the legal right to a break. Kirsty McHugh, CEO of Carers Trust, said: 'It's incredibly disappointing that the UK Government still hasn't given unpaid carers a right to respite. For decades, successive governments have depended on unpaid carers to provide social care on the cheap, which has delayed the need to come up with long-term funding and support. 'Whilst the government is focused on strengthening employment rights, it seems to have forgotten unpaid carers – who can't take a break at all.'
